The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia

详细信息    查看全文

• 作者：Kotaro Hatta ; Hiroshi Takebayashi ; Yasuhiko Sudo ; Shigemasa Katayama ; Masataka Kasuya ; Yutaka Shirai ; Fumiyoshi Morikawa ; Reiko Nakase ; Masato Nakamura ; Shin Ito ; Hironori Kuga ; Mitsuru Nakamura ; Tohru Ohnuma ; Chie Usui ; Hiroyuki Nakamura ; Toyoaki Hirata ; Yutaka Sawa ; for the JAST study group
• 关键词：Serum concentration ; Risperidone ; Negative symptom ; Emergency ; Randomized clinical trial
• 刊名：Psychiatry Research
• 出版年：15 December, 2013
• 年：2013
• 卷：210
• 期：2
• 页码：396-401
• 全文大小：295 K

文摘

We examined clinical characteristics including serum olanzapine concentrations for acute schizophrenia patients who required above conventional doses. We performed a rater-blinded, randomized clinical trial in 12 psychiatric emergency sites. Eligible patients were 18-64 years old and met diagnostic criteria for schizophrenia, acute schizophrenia-like psychotic disorder, or schizoaffective disorder. A total of 42 patients were randomly assigned by means of sealed envelopes to receive risperidone (3-12 mg/day; n=20) and olanzapine (10-40 mg/day; n=22), with follow-up at 8 weeks. The Negative score of the Positive and Negative Syndrome Scale was significantly higher in patients who required high doses than in patients who responded to conventional doses. Serum olanzapine concentrations at the time of oral 20 mg/day could be obtained from 5 out of 7 patients who subsequently required high-dose olanzapine. All values were more than 30 ng/mL after 11-16 h from dosing to sample collection, and the mean value was 47.876 (S.D. 21.546) ng/mL. Such concentrations are appropriate with respect to a therapeutic range of 20-50 ng/mL. The present study has shown evidence that the reason for requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.